Singapore: maintaining top position in Asia for IP rights protection
In recognition of its robust Intellectual Property (IP) rights protection, Singapore ranks top again in Asia in the 2019 edition of the International Property Rights Index (IPRI). Globally, Singapore moved...
In recognition of its robust Intellectual Property (IP) rights protection, Singapore ranks top again in Asia in the 2019...
Read More
China update: IP section in the China-US trade deal (phase one)
On 15th January 2020, the Governments of the United States of America and the People’s Republic of China signed the phase one documentation of a new Economic and Trade...
On 15th January 2020, the Governments of the United States of America and the People’s Republic of China signed...
Read More
Indonesia – Extension of time for payment of outstanding patent annuities
In our previous news alerts dated 13th February 2019 and 28th September 2018 on non-payment of outstanding patent annuities in Indonesia, we reported that the Indonesia Directorate General of...
In our previous news alerts dated 13th February 2019 and 28th September 2018 on non-payment of outstanding patent annuities...
Read More
Invention ownership and patents: the importance of written agreements
Patent rights for an invention can be challenged if ownership is not 'rock-solid'. Written agreements play an important role in determining ownership and patent rights to an invention, and use of the...
Patent rights for an invention can be challenged if ownership is not 'rock-solid'. Written agreements play an important role in determining...
Read More
China update: changes in Guidelines for Examination related to inventions in the fields of artificial intelligence (AI), internet +, big data and block chain
On 31 December, 2019 a new amendment to the Guidelines for Examination of the Chinese National Intellectual Property Administration (CNIPA) was announced. The new guidelines, which come into effect on February...
On 31 December, 2019 a new amendment to the Guidelines for Examination of the Chinese National Intellectual Property Administration (CNIPA) was...
Read More
Biosimilars in Australia
A ‘biosimilar medicine’ or ‘biosimilar’ is a highly similar, but not identical, version of an original biological medicine (‘reference medicine’) – a medicine comprised of large complex molecules derived...
A ‘biosimilar medicine’ or ‘biosimilar’ is a highly similar, but not identical, version of an original biological medicine (‘reference...
Read More
Conference poster presentations as prior art for the assessment of novelty of a later patent application
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions where researchers present their findings. Conferences help generate interest in the scientific community...
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions...
Read More
The status of Australia’s innovation patent – how full is the glass?
The “glass half empty” headline: Innovation patent spends Christmas on death row. The “glass half full” headline: Innovation patent lives to fight another day (year). Notwithstanding, optimistic and the pessimistic angles...
The “glass half empty” headline: Innovation patent spends Christmas on death row. The “glass half full” headline: Innovation patent lives...
Read More